Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 3/20 | 0.46 |
| ▸ | PDE5A | O76074 | 2/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.44 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.34 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.34 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.34 |
| ▸ | GRIK4 | Q16099 | 1/20 | 0.34 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9091457 | 0.83 | PDE9A (0.45) | PDE9APDE5AGRIA1GRIA2GRIA3 | |
| SCHEMBL9080896 | 0.79 | PDE9A (0.70) | PDE9APDE5AGRIA1GRIA2GRIA3 | |
| SCHEMBL8364549 | 0.79 | PDE5A (0.43) | PDE9APDE5AGRIA1GRIA2GRIA3 | |
| SCHEMBL8365191 | 0.78 | GRIA1 (0.42) | PDE9APDE5AGRIA1GRIA2GRIA3 | |
| SCHEMBL8186930 | 0.78 | PDE5A (0.42) | PDE9APDE5AGRIA1GRIA2GRIA3 | |
| SCHEMBL8362326 | 0.76 | GRIA1 (0.43) | PDE9APDE5AGRIA1GRIA2GRIA3 | |
| SCHEMBL8362082 | 0.76 | PDE5A (0.42) | PDE9APDE5AGRIA1GRIA2GRIA3 | |
| SCHEMBL8368431 | 0.75 | GRIA1 (0.42) | PDE9APDE5AGRIA1GRIA2GRIA3 | |
| SCHEMBL8366433 | 0.72 | PDE5A (0.39) | PDE9APDE5AGRIA1GRIA2GRIA3 | |
| SCHEMBL9080386 | 0.72 | GRIA1 (0.45) | GRIA1GRIA2GRIA3GRIA4GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2404922-A1 | QUINOXALINE COMPOUNDS | Astellas Pharma Inc. (JP) | 2012-01-11 | — | — | EP | claimed |
| US-20110319385-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-12-29 | — | — | US | claimed |
| US-5559106-A | Heterocyclic compounds, their use and preparation | NOVO NORDISK A/S (DK) | 1996-09-24 | — | — | US | claimed |
| EP-2404922-B1 | QUINOXALINE COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2016-11-09 | — | — | EP | disclosed |
| US-8674096-B2 | Substituted imidazo[1,5-a]quinoxalin-4-ones as phosphodiesterase 9 inhibitors | ASTELLAS PHARMA INC. (JP) | 2014-03-18 | — | — | US | disclosed |
| US-20130085134-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-04 | — | — | US | disclosed |
| US-8357688-B2 | Substituted imidazo[1,5-a]quinoxalin-4(5H)-ones as PDE9 inhibitors | ASTELLAS PHARMA INC. (JP) | 2013-01-22 | — | — | US | disclosed |
| EP-2404922-A1 | QUINOXALINE COMPOUNDS | Astellas Pharma Inc. (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-20110319385-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-12-29 | — | — | US | disclosed |
| US-5559106-A | Heterocyclic compounds, their use and preparation | NOVO NORDISK A/S (DK) | 1996-09-24 | — | — | US | disclosed |
| EP-0691969-A1 | [1,2,4] TRIAZOLO [4,3-a] QUINOXALINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1996-01-17 | — | — | EP | disclosed |
| WO-1994021639-A1 | [1,2,4] TRIAZOLO [4,3-a] QUINOXALINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085134-A1 | QUINOXALINE COMPOUND | PDE9A, PDE2A, PDE3A | PDE9A 1/4885PDE5A 4/4885GRIA1 3726/4885 |
| US-20110319385-A1 | QUINOXALINE COMPOUND | PDE9A, PDE5A, PDE3A | PDE9A 1/4885PDE5A 2/4885GRIA1 4687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.